Congratulations to Ana Maria Moreno of Navega Therapeutics. Ana was recently awarded the high honor of Student/Alumni Innovator of the Year at this year's Chancellor's Innovation Awards. Here's your chance to learn all about her incredible startup. Navega Therapeutics has created an AI-enabled platform to develop epigenetic therapies that enable them to modulate gene expression at the DNA level without editing or nicking the genome. Their lead indication is in trigeminal neuralgia (TN), which affects 400,000 people in the US and Europe. TN is also referred to as the "suicide disease" based on the high levels of facial pain experienced by these patients. NT-Z001 targets the sodium channel, Nav1.7, which is responsible for pain signal transmission. Their therapy would be a single injection that downregulates this gene, providing a non-addictive, long-lasting therapy for chronic pain. Additional programs in their pipeline include therapies in rheumatoid arthritis and osteoarthritis, which not only relieve pain, but also have disease modifying effects. To learn more about Navega Therapeutics- https://navegatx.com/en To learn more about the Chancellor's Innovation Awards- https://lnkd.in/g6VHZkmG Watch the full video below... And stay tuned for more videos of this year's winners and finalists all next week! ? Corinne Peek-Asa, Pradeep Khosla, Paul Roben, Tim Schwartz, Marie Christensen, Lisel Gorell-Getz, M.A., Shane Moise, Christine Liou, Jacques Chirazi, Christiana Russell, M.Ed, Priya Sinha Cloutier, IGE UC San Diego, National Science Foundation (NSF), Debra Bass, APR, Cheryl P. Robinson, APR, Kellie Woodhouse ? #whereinnovatorsconnect, #designandinnovation, #Officeofinnovationandcommercialization, #Innovation, #UCSanDiego, #entrepreneurship, #startup, #biotech, #Genetherapy, #Painmanagement, #NonOpioidPainRelief
Navega Therapeutics
生物技术研究
San Diego，CA 1,984 位关注者
We are harnessing the precision of CRISPR and zinc finger epigenome regulation to enable next-generation gene therapies.
关于我们
Around 1.5 billion people around the world suffer from chronic pain, with more than 100 million in the US alone. Conventional treatment for chronic pain consists mostly of opioid narcotics. However, opioids have failed us as the United States is currently undergoing an opioid epidemic. Sadly, over 120 Americans die each day of an opioid overdose. We have developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific and long-lasting. So how does this work? We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way. In our proof of concept, we have demonstrated that the mice that received our therapy have an increased pain tolerance and lower pain levels. Importantly, mice are not numb and can continue feeling mechanical stimulation, such as touch. We believe that patients should not have to decide whether they live a life with pain, or one with the risk of addiction.
- 网站
-
https://www.navegatx.com
Navega Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Diego，CA
- 类型
- 私人持股
- 创立
- 2018
- 领域
- Biopharma、Pain Management和Gene Therapy
地点
-
主要
获取路线
US，CA，San Diego，92122
Navega Therapeutics员工
动态
-
???Exciting News from Navega Therapeutics!??? We are thrilled to announce the addition of four distinguished advisors to our team! These industry leaders bring over 125 years of combined experience in gene therapy, AAV manufacturing, and business strategy, enhancing our mission to pioneer groundbreaking epigenetic therapies. Meet Our Advisors: *Jeffrey M. Ostrove, Ph.D.: Dr. Ostrove brings a wealth of experience as a serial entrepreneur with a notable track record in gene therapy and multiple successful exits in the biotech sector.? *Chris Mason, MD, Ph.D.:??Dr. Mason brings over 30 years of cell and gene therapy expertise spanning R&D, clinical medicine, manufacturing, and commercialization.? *Daniel Bradbury: Daniel Bradbury, former CEO of Amylin Pharmaceuticals, brings extensive leadership experience and strategic market insights, honed over years of guiding biopharmaceutical companies to success.? *Diego Miralles, MD: Dr. Miralles is an accomplished biotech leader known for his pivotal roles as CEO at Laronde and Vividion Therapeutics, and as the former Global Head of J&J Innovation. Join us in welcoming our new advisors. Together, we're making significant strides towards a future where chronic pain can be managed effectively without opioids. https://lnkd.in/gFk3hh-K #Biotech #ChronicPain #Innovation #Healthcare #Epigenetics #SodiumChannels #NavegaTherapeutics #Nav1.7
-
?? Exciting News from Navega Therapeutics! We are thrilled to announce that we have been awarded a $4M grant by the California Institute for Regenerative Medicine (CIRM). This significant funding will support our ongoing efforts to develop innovative gene therapies for the treatment of chronic pain. We are committed to advancing our research and bringing transformative treatments to patients in need. Thank you to CIRM for their support and belief in our mission! #Biotech #GeneTherapy #ChronicPain #CIRMgrant #Innovation https://lnkd.in/gmJVGKVW
-
???Our CEO Featured in Scientific American!??? Our CEO, Ana Moreno, was recently interviewed by?Scientific American?for an insightful article on Vertex’s Suzetrigine and other novel pain medications that target sodium channels and represent a shift away from opioids. This advancement has revitalized the pain therapeutics field, and Navega Therapeutics is leading the charge in developing next-generation pain treatments. By leveraging cutting-edge AI-enabled epigenetic tools to suppress the genes responsible for chronic pain, Navega Therapeutics is at the forefront of developing these next-generation pain treatments. Our ultimate goal is to create long-lasting, non-addictive therapies that can one day replace opioids. With over 51 million Americans suffering from chronic pain, the need for innovative solutions has never been greater. We are proud to contribute to this critical area of research and are committed to transforming the future of pain management. A big thank you to?Marla Broadfoot at Scientific American?for highlighting the work we're doing at Navega Therapeutics. Read the full article here: https://lnkd.in/g3mkr5St #PainManagement #GeneTherapy #Epigenetics #NavegaTherapeutics #Innovation #ChronicPain #ScientificAmerican